ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
A Retrospective Analysis of Small Molecule Targeting Inhibitor Usage for Lung Cancer Among Outpatients in Six Major Regions of China (2016–2022)
Provisionally accepted
- 1Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, China
- 2Quzhou City People's Hospital, Quzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study aimed to evaluate national trends in amounts, prescription volumes, and the rationality of drug use in pharmacoeconomics associated with small molecule targeting inhibitors for lung cancer treatment among adult patients in China from 2016 to 2022. Methods: Prescription data for outpatients diagnosed with lung cancer were extracted from the Hospital Prescription Analysis Cooperative Project database, covering hospitals across six major regions of 77 hospitals. Annual trends in prescription volumes and associated expenditures were analyzed. Additionally, pharmacoeconomic indicators related to small molecule targeting inhibitors were assessed to evaluate cost-effectiveness and utilization patterns. Demographic profiles, regional sources of patients, and classification of small molecule targeting inhibitors were examined. Results: Prescription volumes and amounts for small molecule targeting inhibitors in lung cancer treatment have increased annually. Since 2020, expenditure levels have stabilized. Furthermore, their use is supported by pharmacoeconomic evidence indicating rational and efficient medication utilization. There was a statistically significant increase in total prescriptions (P1 < 0.001) and overall medication expenditures (P2 < 0.001). Conclusion: Between 2016 and 2022, the prescription volume of small molecule targeted inhibitors for lung cancer rose yearly, showing their expanding clinical use. Since 2020, despite continued growth in prescriptions, drug costs have stabilized or slightly decreased. This reflects that China's medical insurance negotiation and centralized procurement policies have effectively reduced patients' economic burden without limiting their access to these inhibitors. Pharmacoeconomic indicators also confirm that the use of these drugs has been both reasonable and efficient, allowing for increased drug utilization while reducing patients' financial strain.
Keywords: lung cancer, Small molecule targeting inhibitors, Outpatient Prescription Trends, Pharmacoeconomics, targeted therapy
Received: 06 Sep 2025; Accepted: 24 Oct 2025.
Copyright: © 2025 Bo, 晨, Chen, Hu, Yuzhen, Li, Kaili and Qiu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liu-Cheng Li, liliuchengsrrsh@zju.edu.cn
Mao Kaili, 1258371506@wmu.edu.cn
Jiang Qiu, 13587001436@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.